Lihua Chen

Prof. Lihua Chen

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JMJifei Miao
Jifei Miao
LCLihua Chen
Lihua Chen
XPXiaojin Pan
Xiaojin Pan
LLLiqing Li
Liqing Li
BZBeibei Zhao
Beibei Zhao
JLJiao Lan
Jiao Lan

10 May 2024 in Medicine
Verified
Journal Article
Open access
LCLihua Chen
Lihua Chen
YZYu Zhao
Yu Zhao
JQjingjing QIU
jingjing QIU
XLxiaosheng lin
xiaosheng lin
Postmenopausal osteoporosis (PMOP) is a common metabolic inflammatory disease. In conditions of estrogen deficiency, chronic activation of the immune system leads to a hypo-inflammatory phenotype and alterations in its cytokine and immune cell profile, although immune cells play an important role in the pathology of osteoporosis, studies on this have been rare. Therefore, it is important to investigate the role of immune cell-related genes in PMOP. PMOP-related datasets were downloaded from the Gene Expression Omnibus database. Immune cells scores between high bone mineral density (BMD) and low BMD samples were assessed based on the single sample gene set enrichment analysis method. Subsequently, weighted gene co-expression network analysis was performed to identify modules highly associated with immune cells and obtain module genes. Differential analysis between high BMD and low BMD was also performed to obtain differentially expressed genes. Module genes are intersected with differentially expressed genes to obtain candidate genes, and functional enrichment analysis was performed. Machine learning methods were used to filter out the signature genes. The receiver operating characteristic (ROC) curves of the signature genes and the nomogram were plotted to determine whether the signature genes can be used as a molecular marker. Gene set enrichment analysis was also performed to explore the potential mechanism of the signature genes. Finally, RNA expression of signature genes was validated in blood samples from PMOP patients and normal control by real-time quantitative polymerase chain reaction. Our study of PMOP patients identified differences in immune cells (activated dendritic cell, CD56 bright natural killer cell, Central memory CD4 T cell, Effector memory CD4 T cell, Mast cell, Natural killer T cell, T follicular helper cell, Type 1 T-helper cell, and Type 17 T-helper cell) between high and low BMD patients. We obtained a total of 73 candidate genes based on modular genes and differential genes, and obtained 5 signature genes by least absolute shrinkage and selection operator and random forest model screening. ROC, principal component analysis, and t-distributed stochastic neighbor embedding down scaling analysis revealed that the 5 signature genes had good discriminatory ability between high and low BMD samples. A logistic regression model was constructed based on 5 signature genes, and both ROC and column line plots indicated that the model accuracy and applicability were good. Five signature genes were found to be associated with proteasome, mitochondria, and lysosome by gene set enrichment analysis. The real-time quantitative polymerase chain reaction results showed that the expression of the signature genes was significantly different between the 2 groups. HIST1H2AG, PYGM, NCKAP1, POMP , and LYPLA1 might play key roles in PMOP and be served as the biomarkers of PMOP.

20 December 2025 in International Immunopharmacology
Verified
Journal Article
Open access
YZYu Zhao
Yu Zhao
MGMin Gao
Min Gao
FWFan Wang
Fan Wang
LPLei Pang
Lei Pang
HLHaibo Li
Haibo Li
LCLihua Chen
Lihua Chen
Gout is a systemic metabolic disease with rising prevalence and complex etiology, yet its molecular mechanisms remain incompletely defined. Multi-omics Mendelian randomization (MR) enables causal prioritization of genes implicated in gout. Because the gut microbiota (GM) can modulate urate metabolism and inflammation, integrating microbiome analyses may help nominate potential therapeutic candidates. This study aimed to nominate candidate targets for gout by integrating multi-omics MR, clinical validation, GM analysis, and in-silico druggability assessment. We performed multi-omics MR (pQTL/eQTL/mQTL) to prioritize genes with putative causal effects on gout risk. Candidate gene expression patterns were examined in a public single-cell RNA sequencing dataset to determine their distribution across immune cell subtypes and functional context. Associations between identified candidate genes and GM composition were evaluated using the MiBioGen database. Potential therapeutic interactions were predicted through the Comparative Toxicogenomics Database (CTD). Expression of candidate genes was validated in peripheral blood samples from 51 gout patients and 50 healthy controls by quantitative real-time polymerase chain reaction (qRT-PCR). Finally, molecular docking and molecular dynamics (MD) simulations were conducted to explore binding poses and stability between prioritized proteins and predicted drugs. MR analysis identified four gout-associated genes (BAIAP2, CD248, GCHFR, and ABHD14B). Among them, BAIAP2, CD248, and GCHFR showed significant causal relationships with specific gut microbial taxa in MiBioGen, whereas ABHD14B showed no GM associations. CTD-based drug prediction further highlighted three compounds-benzbromarone, calcitriol, and cyclosporine-potentially targeting these genes. In an independent cohort (51 gout vs. 50 controls), qRT-PCR confirmed GCHFR dysregulation consistent with MR estimates, and molecular docking plus MD simulations supported stable binding of benzbromarone to GCHFR, providing mechanistic plausibility. This integrative framework convergently prioritizes GCHFR as a candidate for therapeutic investigation in gout and identifies CD248, BAIAP2, and ABHD14B as additional gout-related candidates. These results generate testable hypotheses for GCHFR-focused mechanistic and therapeutic studies, as well as further functional studies of the other genes.

8 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
JQJingjing Qiu
Jingjing Qiu
YZYu Zhao
Yu Zhao
ZDZilan Deng
Zilan Deng
JHJuxiu Huang
Juxiu Huang
YZYanlin Zhang
Yanlin Zhang
LCLihua Chen
Lihua Chen
Objective: To explore the pathogenesis of menopausal osteoporosis (MOP) based on bioinformatics. Furthermore, to explore the therapeutic mechanism of Wuzi Yanzong Pill(WZYZP) against MOP using network pharmacology and molecular docking. Methods: The GEO datasets were applied to determine the differentially expressed genes (DEGs) between MOP and the controls. The Traditional Chinese Medicine Systems Pharmacology and Analysis Platform (TCMSP) database was used to obtain the main active components and corresponding targets penetrating the blood-brain barrier(BBB) in WZYZP. The targets related to MOP were obtained by GeneCards, Online Mendelian Inheritance in Man (OMIM), Drugbank, the Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), and DisGeNET databases. The potential targets of WZYZP for the intervention of MOP were obtained by intersection with compound targets. Cytoscape software was used to construct the network diagram of WZYZP in the treatment of MOP. The protein-protein interaction (PPI) network was performed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. The core targets were screened according to the node degree value. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of core targets were finished by Database for Annotation, Visualization, and Integrated Discovery (David) database platform, and molecular docking analysis was performed by AutoDock Vina software. The DEGs intersected with the hub genes of WZYZP against MOP. Furthermore, the intersected hub genes were used to predict miRNAs in the Starbase and miRwalk database. The intersection was obtained by the mRNA-miRNA relationship. The intersected hub genes were placed in the AnimalTFdb and JASPAR to predict transcription factors (TFs) and took the intersection of mRNA-TFs. Cytoscape was used to draw the network diagram of mRNA-miRNA and mRNA-TFs relationship pairs. Results: A total of 620 DEGs in GSE100609 were obtained. The top four genes (TP53, SMAD2, STAT1, CXCL8) were screened out as core genes. A total of 59 main active ingredients in WZYZP were screened, and the core active ingredients were quercetin, kaempferol, β-sitosterol, isorhamnetin, and glycitein. There were 131 target genes, including the top five hub genes: TP35, JUN, RELA, AKT1, and MAPK1. The biological process obtained from GO enrichment was mainly related to the regulation of osteoclast differentiation. The enrichment results of KEGG suggested that the effect of WZYZP in the treatment of MOP was focused on the signaling pathways such as estrogen, toll-like receptor, TNF, and osteoclast differentiation. A total of 4 intersections between DEGs and hub genes: TP53, CXCL8, SELE, and STAT1. The network diagram of mRNA-miRNA and mRNA-TFs. comprises 4 mRNAs, 47 TFs, and 66 miRNAs. Through the topology analysis of the network, four transcription factors (SPIB, MAX, NR2F1 and ELK1) significantly affected the expression of hsa-miR-19b-3p and hsa-miR-1294. Conclusion: TP53, SMAD2, STAT1, and CXCL8 genes are of great value in the early diagnosis of MOP. The active ingredients of WZYZP may affect the expression of hsa-miR-19b-3p and hsa-miR-1294 by regulating four transcription factors (SPIB, MAX, NR2F1 and ELK1). These miRNAs may further regulate the expression of genes such as TP53, CXCL8 and STAT1. Ethics and dissemination: This study dose not require ethical approval of an ethical committee because it will not show personal information and will not infringe the privacy of the participants.

27 October 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYu Zhao
Yu Zhao
TNTra My Nguyen
Tra My Nguyen
FWFan Wang
Fan Wang
YLYijin Li
Yijin Li
ZXZhicong Xia
Zhicong Xia
XLxiaosheng lin
xiaosheng lin
Type 2 diabetes (T2D) and osteoporosis (OP) frequently coexist, but the molecular features linking metabolic dysfunction to impaired bone remodeling remain incompletely defined. Here, we integrated public bulk transcriptomic datasets, a clinical serum proteomics cohort, and descriptive single-cell resources to prioritize candidates for investigation in a T2D-OP mouse model. The existing differential-expression screens, weighted gene co-expression network analysis (WGCNA) and set intersections nominated TTC1. A documented TTC1 expression-stratified GSEA in the low-versus-high BMD dataset was used for exploratory pathway context; it was not a disease-case-control enrichment analysis and did not apply a p-value adjustment method. These analyses are hypothesis-generating: TTC1 met the nominal screening criteria but did not meet BH-FDR < 0.05 in the low-versus-high BMD transcriptomic or serum proteomic results, and the T2D bulk analysis did not account for longitudinal sampling. Pre-imputation serum TTC1 measurements were available in only 1/14 controls and 6/14 patients, and TTC1 was excluded by detection-coverage filters. Single-cell analyses provided cellular context without cross-study disease-effect inference. In the T2D-OP mouse model, bone microstructural deterioration and histopathological damage were accompanied by increased TTC1, TNF-α, iNOS, NFATc1 and TRAP expression and reduced RUNX2 and OCN expression in bone tissue. The combined observations motivate further study of TTC1 in abnormal bone remodeling; independent clinical validation and functional perturbation are needed to establish its biological role.